RAPP Rapport Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2012593 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-54.0%
TTM EPS YoY-39.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-33.3%
ROA-31.5%
ROIC (approx.)-45.9%
Asset turnover—
Leverage & solvency
Liabilities / assets6.5%
Debt / equity0.00x
Current ratio20.07x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $94.79M | $60.94M | $28.00M |
| SG&A expense | $30.31M | $22.12M | $8.18M |
| Operating income | -$125.10M | -$83.06M | -$36.18M |
| Pretax income | — | -$78.31M | -$34.78M |
| Income tax | $0 | $0 | $10,000 |
| Net income | -$111.48M | -$78.31M | -$34.79M |
| EBITDA | -$124.08M | -$82.22M | -$36.07M |
| EPS (basic) | -2.86 | -3.78 | -23.10 |
| EPS (diluted) | -2.86 | -3.78 | -23.10 |
| Weighted avg. shares (diluted) | 38.93M | 20.74M | 1.51M |
| Balance sheet | |||
| Cash & equivalents | $52.65M | $56.80M | $70.17M |
| Short-term investments | $437.89M | $248.47M | $77.31M |
| Receivables | $0 | — | — |
| Current assets | $498.56M | $309.80M | $150.87M |
| PP&E, net | $2.98M | $3.53M | $1.92M |
| Total assets | $512.43M | $314.93M | $155.42M |
| Current liabilities | $19.05M | $8.77M | $8.80M |
| Total liabilities | $27.78M | $9.51M | $14.48M |
| Shareholders' equity | $484.65M | $305.43M | -$25.63M |
| Shares outstanding | 47.77M | 36.58M | 4.17M |
| Cash flow statement | |||
| Operating cash flow | -$87.47M | -$64.83M | -$27.18M |
| Capital expenditure | $616,000 | $2.40M | $1.64M |
| Free cash flow | -$88.09M | -$67.23M | -$28.82M |
| Investing cash flow | -$187.47M | -$170.14M | -$78.86M |
| Financing cash flow | $270.79M | $221.62M | $145.14M |
| Depreciation & amortization | $1.02M | $839,000 | $112,000 |
| Stock-based compensation | $18.86M | $10.23M | $3.52M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.